The Dendreon Difference
Pioneers in Cellular Therapy
Targeting cancer, transforming lives
Dendreon is a commercial-stage biopharmaceutical company and end-to-end provider of manufacturing services for the cell therapy market. Founded on the belief that immunotherapy made from a patient’s own cells will transform disease treatment, Dendreon has worked tirelessly to make the fight against cancer personal.
Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy to harness the innate benefits of personalized cellular treatment made from a patient’s own immune cells.
Since its FDA-approval in 2010, nearly 40,000 men have been prescribed PROVENGE. Now Dendreon is helping to advance other cell therapies from clinic to market by leveraging the extensive experience of developing and commercializing PROVENGE.
Dendreon paved the way as the first FDA-approved cell therapy made from a patient’s own immune cells. Prior to the development of PROVENGE, there was no roadmap for how to establish and monitor critical process parameters, or the potency and stability of cellular therapeutics. Our work established such processes. Building on our achievements, we are now working with partners to provide the end-to-end manufacturing services and regulatory expertise needed to commercialize new treatments. Our hope is that by pushing research forward, we may change the lives of patients and their families.
Our Culture
Improving the lives of patients through innovative science and cellular therapies.
At Dendreon, we have a singular purpose: improving the lives of patients through innovative science and cellular therapies.
We enable the future of complex cell therapies through research, development, and strategic partnerships. By leveraging innovative science that delivers unique therapies, our work helps change lives.
Mission & Values
Our patients are at the heart of what we do daily. We delivered the first autologous cell therapy to the market over a decade ago, and continue to drive the future of cell therapy to serve more patients and their families.
Our History
1992
Inspired by their research at Stanford School of Medicine, Edgar Engleman and Samuel Strober establish Activated Cell Therapy.
1993
Activated Cell Therapy opens its first R&D facility.
1995
The Antigen Delivery Cassette™ is developed, which will become the basis of the Active Cellular Immunotherapy platform.
1997
Activated Cell Therapy changes its name to Dendreon.
1999
Dendreon moves its headquarters to Seattle, Washington.
2000
Dendreon enters the NASDAQ with an IPO of $45 million to fund trials and preclinical activities for therapeutic cancer vaccines.
2001
Dendreon is awarded a US patent (No. 6,210,662) for the composition of sipuleucel-T.
2003
Phase III IMPACT study evaluating sipuleucel-T in men with advanced prostate cancer begins.
2003
Study results eventually serve as the basis for US Food and Drug Administration (FDA) approval.
2006
Dendreon completes Biologics License Application (BLA) submission to the FDA — the first BLA for an active cellular immunotherapy for cancer.
2007
The FDA’s Advisory Committee votes in favor of the safety and efficacy of PROVENGE, advancing sipuleucel-T toward FDA approval.
2007
Patients and advocates rally for PROVENGE after the FDA requests additional efficacy data.
2009
Dendreon completes Phase III IMPACT clinical trial and reports positive topline results.
2010
Dendreon receives FDA approval for sipuleucel-T (PROVENGE), the first FDA-approved immunotherapy made from a patient’s own immune cells.
2010
Commercial manufacturing of PROVENGE begins in Morris Plains, New Jersey.
2010
The New England Journal of Medicine publishes results of the IMPACT trial demonstrating that PROVENGE extends median overall survival for men with advanced prostate cancer by 4.1 months.
2011
The FDA approves PROVENGE manufacturing sites in Seal Beach, California and Union City, Georgia.
2013
More than 10,000 men prescribed PROVENGE.
2014
The National Comprehensive Cancer Network (NCCN) recommends PROVENGE for first-line use in patients with M1 CRPC.
2015
Valeant Pharmaceuticals acquires Dendreon for $495 million.
2015
More than 20,000 men prescribed PROVENGE.
2016
Dendreon delivers first profitable year since its inception.
2017
Dendreon resumes operations as a standalone company following acquisition by Sanpower Group for $819.9 million.
2017
Dendreon reports its most profitable year in the company’s history.
2018
Over 30,000 men prescribed PROVENGE.
2020
Dendreon celebrates 10th anniversary of the FDA’s approval of PROVENGE.
2022
Nearly 40,000 men have received PROVENGE
State-of-the-Art Facilities
Our state-of-the-art Immunotherapy Manufacturing Facilities (IMF) provide end-to-end manufacturing services for the cell therapy market.
Seal Beach, CA
- Corporate and Commercial Headquarters
- Commercial and Clinical Manufacturing
- Facility FDA approved in 2011
- 180,00+ square foot facility
Union City, GA
- Commercial and Clinical Manufacturing
- Facility FDA approved in 2011
- 170,000+ square foot facility
Seattle, WA
- Patient Operations
- Medical Organization
- Research & Manufacturing Services
- Clinical & Medical Affairs
- Regulatory Affairs & Pharmacovigilance
Corporate Governance
Our patients, their families, and the physicians who treat them are counting on us to conduct business with honesty and integrity. We value our relationship with our employees, partners, contractors, vendors, and the communities in which we operate and hold ourselves to a high ethical standard. Dendreon follows all relevant laws, regulations, guidelines, and codes concerning the pharmaceutical industry.